10x Genomics, Inc. (TXG) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $32.17 (-0.19%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 2, 2026 | Daniel Arias | Stifel Nicolaus | $25.00 | -22.3% |
| Feb 13, 2026 | Kyle Mikson | Canaccord Genuity | $22.00 | -31.6% |
| Dec 1, 2025 | Kallum Titchmarsh | Morgan Stanley | $20.00 | -37.8% |
| Aug 11, 2025 | Kyle Mikson | Canaccord Genuity | $16.00 | -50.3% |
| Aug 8, 2025 | Dan Leonard | UBS | $13.00 | -59.6% |
| Aug 8, 2025 | Justin Bowers | Deutsche Bank | $14.00 | -56.5% |
| Aug 13, 2024 | Tejas Savant | Morgan Stanley | $46.00 | +43.0% |
| Jul 23, 2024 | Kyle Mikson | Canaccord Genuity | $32.00 | -0.5% |
| Jul 10, 2024 | Justin Bowers | Deutsche Bank | $25.00 | -22.3% |
| Jun 28, 2024 | Luke Sergott | Barclays | $24.00 | -25.4% |
| Jun 3, 2024 | Tycho Peterson | Jefferies | $24.00 | -25.4% |
| May 1, 2024 | Luke Sergott | Barclays | $36.00 | +11.9% |
| Apr 10, 2024 | Luke Sergott | Barclays | $45.00 | +39.9% |
Top Analysts Covering TXG
TXG vs Sector & Market
| Metric | TXG | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.62 | 2.24 | 2.40 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | -22.6% | +11475.1% | +17.1% |
| P/E Ratio | -62.37 | 3.97 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $608M | $613M | $618M | 12 |
| 2027-03-31 | $152M | $155M | $158M | 5 |
| 2027-06-30 | $156M | $160M | $162M | 5 |
| 2027-09-30 | $161M | $165M | $168M | 5 |
| 2027-12-31 | $174M | $178M | $181M | 5 |
| 2028-03-31 | $156M | $160M | $163M | 4 |
| 2028-06-30 | $164M | $168M | $171M | 4 |
| 2028-09-30 | $168M | $172M | $175M | 4 |
| 2028-12-31 | $184M | $189M | $191M | 4 |
| 2029-12-31 | $776M | $796M | $817M | 5 |
| 2030-12-31 | $829M | $850M | $873M | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.49 | $-0.90 | $-0.10 | 8 |
| 2027-03-31 | $-0.21 | $-0.21 | $-0.20 | 1 |
| 2027-06-30 | $-0.16 | $-0.16 | $-0.15 | 1 |
| 2027-09-30 | $-0.14 | $-0.14 | $-0.14 | 1 |
| 2027-12-31 | $-0.10 | $-0.10 | $-0.09 | 1 |
| 2028-03-31 | $-0.37 | $-0.36 | $-0.35 | 2 |
| 2028-06-30 | $-0.14 | $-0.14 | $-0.14 | 2 |
| 2028-09-30 | $-0.14 | $-0.14 | $-0.14 | 2 |
| 2028-12-31 | $-0.05 | $-0.05 | $-0.05 | 2 |
| 2029-12-31 | $-0.42 | $-0.40 | $-0.39 | 4 |
| 2030-12-31 | $-0.32 | $-0.31 | $-0.30 | 4 |
Frequently Asked Questions
What is the analyst consensus for TXG?
The consensus among 16 analysts covering 10x Genomics, Inc. (TXG) is Hold with an average price target of $22.14.
What is the highest price target for TXG?
The highest price target for TXG is $46.00, set by Tejas Savant at Morgan Stanley on 2024-08-13.
What is the lowest price target for TXG?
The lowest price target for TXG is $13.00, set by Dan Leonard at UBS on 2025-08-08.
How many analysts cover TXG?
16 analysts have issued ratings for 10x Genomics, Inc. in the past 12 months.
Is TXG a buy or sell right now?
Based on 16 analyst ratings, TXG has a consensus rating of Hold (2.62/5) with a -22.6% upside to the consensus target of $22.14.
What are the earnings estimates for TXG?
Analysts estimate TXG will report EPS of $-0.90 for the period ending 2026-12-31, with revenue estimated at $613M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.